We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-0.2%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$174M
AUM Growth
–
Cap. Flow
+$152M
Cap. Flow %
87.51%
Top 10 Hldgs %
61.99%
Holding
46
New
46
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$14.6M
2
ARRY
Array Biopharma Inc
ARRY
+$14.1M
3
SNY icon
Sanofi
SNY
+$8.67M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.61M
5
TSRO
TESARO, Inc.
TSRO
+$8.41M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 75.41%
2 Miscellaneous 13.82%
3 Industrials 4.17%
4 Real Estate 3.32%
5 Financials 3.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXGN icon
26
Axogen
AXGN
$2.77B
$1.63M 0.94%
+57,723
New +$1.36M
ABMD
27
DELISTED
Abiomed Inc
ABMD
$1.61M 0.93%
+8,594
New +$1.6M
GBT
28
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.53M 0.88%
+38,800
New +$1.45M
PCRX icon
29
Pacira BioSciences
PCRX
$1.03B
$1.15M 0.66%
+25,100
New +$995K
CLVS
30
DELISTED
Clovis Oncology, Inc.
CLVS
$1.11M 0.64%
+16,397
New +$1.15M
BCRX icon
31
BioCryst Pharmaceuticals
BCRX
$2.51B
$974K 0.56%
+198,319
New +$961K
MGLN
32
DELISTED
Magellan Health Services, Inc.
MGLN
$896K 0.52%
+9,282
New +$821K
ALGN icon
33
Align Technology
ALGN
$11.2B
$889K 0.51%
+4,000
New +$909K
VREX icon
34
Varex Imaging
VREX
$780M
$832K 0.48%
+20,700
New +$744K
IRMD icon
35
iRadimed
IRMD
$1.11B
$774K 0.45%
+51,059
New +$649K
ABUS icon
36
Arbutus Biopharma
ABUS
$1B
$543K 0.31%
+107,495
New +$630K
ASND icon
37
Ascendis Pharma A/S
ASND
$16.3B
$485K 0.28%
+12,118
New +$441K
ISEE
38
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$465K 0.27%
+149,100
New +$419K
CIVI
39
DELISTED
Civitas Solutions, Inc.
CIVI
$402K 0.23%
+23,529
New +$437K
ARDM
40
DELISTED
Aradigm Corp Common Stock
ARDM
$349K 0.2%
+52,115
New +$229K
CDTX
41
DELISTED
Cidara Therapeutics
CDTX
$340K 0.2%
+2,500
New +$379K
SPNE
42
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$313K 0.18%
+30,899
New +$317K
IVTY
43
DELISTED
Invuity, Inc
IVTY
$279K 0.16%
+45,000
New +$366K
SRRA
44
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$250K 0.14%
+1,675
New +$161K
NGNE icon
45
Neurogene
NGNE
$732M
$235K 0.14%
+1,000
New +$234K
QTNT
46
DELISTED
Quotient Limited Ordinary Shares
QTNT
$52K 0.03%
+263
New +$50.5K
1
2

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q4 2017 Portfolio in Review

Q4 2017 is the first quarter with a 13F filing on record for Eversept Partners, which disclosed 46 positions worth $174M. Its ten largest holdings account for 62% of the portfolio.

Its largest position is Aerie Pharmaceuticals: 241,480 shares worth $14.4M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, followed by Miscellaneous and Industrials.

  • Eversept Partners's largest Q4 2017 buy was Aerie Pharmaceuticals: 241,480 shares worth $14.4M.
  • Eversept Partners's ten largest holdings make up 62% of its $174M portfolio in Q4 2017.
  • Eversept Partners disclosed 46 positions in Q4 2017, its first 13F filing on record.

Based on Eversept Partners's 13F filing for Q4 2017, filed 12 Feb 2018.